ClinicalTrials.gg
Status unknownNCT06158061Updated Dec 6, 2023

Assessment of Serum and Tissue Tryptase Levels in Acne Vulgaris Patients

An interventional study of tryptase enzyme level in Acne Vulgaris, sponsored by Sohag University. Status unknown at 1 site in Egypt. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-06.

Sponsored by Sohag University · Not applicable, Interventional, and Diagnostic

The sponsor has not verified this record recently (last verified Nov 2023), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Acne vulgaris is an inflammatory disorder of pilosebaceous glands. Acne is a highly prevalent inflammatory disease affecting approximately 9.4% of the world's population , and estimated up to 90% among adolescents. By natural course acne starts at 7-12 ages and mostly resolves by the third decade of individuals life .

Mast cells may play important role in maintenance of physiological functions of our body; they also have a role in pathological and inflammatory mechanisms of many diseases. Tryptase is suggested to be important for survival as no tryptase-deficient human subject has yet been reported. Tryptase is mainly synthesized by mast cells but a very low amount may originate in basophil with no interference with total levels of the enzyme. Tryptase is currently considered as a metabolic signaling and effector mediator for acute mast cell degranulation and late phase of allergy and inflammation .

02

Conditions studied

  • Acne Vulgaris

Browse trials for

03

In context

Acne Vulgaris

750 studies on the registry are indexed under Acne Vulgaris; 89 are open to participants now.

This study's planned enrollment of 90 is above the median of 69 across 647 interventional studies indexed under Acne Vulgaris.

Browse Acne Vulgaris studies →

Lead sponsor

Sohag University is the lead sponsor of 1,218 studies on the registry; 627 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with acne vulgaris ≥ 18 years old, both male and female patients will be included.

Exclusion criteria

Exclusion Criteria:

  • Patients with the following criteria will be excluded from our study: 1- Pregnancy and breast feeding women. 2- Women on hormonal contraceptions. 3- Patients on topical/systemic treatment for AV during the last 6 months prior to the study. 4- Patients with other dermatological diseases e.g. psoriasis, vitiligo, DLE, etc. 5- Patients suffering from chronic medical illness such as; diabetes mellitus, thyroid disease, and cancer.
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Active comparator
    patient group

    Patients with acne vulgaris ≥ 18 years old, both male and female patients will be included.

    Diagnostic Test: tryptase enzyme level

  • Active comparator
    control group

    healthy controls without acne vulgaris or other dermatological diseases like psoriasis, vitiligo, DLE

    Diagnostic Test: tryptase enzyme level

Interventions

  • Diagnostic testtryptase enzyme level

    In serum: Three ml blood will be collected from all participants (patients and controls) by aseptic venipuncture into redtop plain glass tubes. Blood samples will be allowed to coagulate during 30-60 minutes. Serum will be obtained by centrifugation at t 1262 g for 10 minutes, aliquoted, and immediately frozen at -20°C until analyzed to determine serum tryptase level. Serum tryptase concentration will be assessed by a commercially available double antibody sandwich enzyme-linked immunosorbent assay (ELISA) kit. In tissue: Punch skin biopsies of 3mm depth will be taken under local anesthesia from back of Acne vulgaris patients and from matched sites of control subjects. Skin biopsies will be fixed in 10% formalin solution, and submitted to Pathology department in our institute for routine tissue processing by special stain for assessment of tissue tryptase level and number of mast cells tissue biopsy.

06

What researchers measure

Primary outcomes

  1. serum tryptase level

    Three ml blood will be collected from all participants (patients and controls) by aseptic venipuncture into redtop plain glass tubes. Blood samples will be allowed to coagulate during 30-60 minutes. Serum will be obtained by centrifugation at t 1262 g for 10 minutes, aliquoted, and immediately frozen at -20°C until analyzed to determine serum tryptase level. Serum tryptase concentration will be assessed by a commercially available double antibody sandwich enzyme-linked immunosorbent assay (ELISA) kit.

    Time frame: 8 months

  2. tissue tryptase level

    Punch skin biopsies of 3mm depth will be taken under local anesthesia from back of Acne vulgaris patients and from matched sites of control subjects. Skin biopsies will be fixed in 10% formalin solution, and submitted to Pathology department in our institute for routine tissue processing by special stain for assessment of tissue tryptase level and number of mast cells tissue biopsy.

    Time frame: 8 months

07

Study locations

1 site
  • Sohag university Hospital
    Sohag, Egypt
    • Magdy M Amin, professor · Contact
08

References and documents

Publications

  • Alanazi MS, Hammad SM, Mohamed AE. Prevalence and psychological impact of Acne vulgaris among female secondary school students in Arar city, Saudi Arabia, in 2018. Electron Physician. 2018 Aug 25;10(8):7224-7229. doi: 10.19082/7224. eCollection 2018 Aug. PubMed 30214705 ↗
  • Saleh HM, Deif MA, El-Husseiny RM. Assessment of serum interleukin-19 in acne vulgaris patients of different clinical severities. J Cosmet Dermatol. 2021 Sep;20(9):3034-3040. doi: 10.1111/jocd.13977. Epub 2021 Feb 13. PubMed 33538078 ↗
  • Jusuf NK, Putra IB, Sari L. Differences of Microbiomes Found in Non-Inflammatory and Inflammatory Lesions of Acne Vulgaris. Clin Cosmet Investig Dermatol. 2020 Oct 22;13:773-780. doi: 10.2147/CCID.S272334. eCollection 2020. PubMed 33122933 ↗
  • Tang L, Yu B, Liao Y, Long S, Yan H, He Q, Li C. Serum Irisin: A Potential Diagnostic Marker for Insulin Resistance in Acne Vulgaris. Indian J Dermatol. 2022 Jul-Aug;67(4):477. doi: 10.4103/ijd.ijd_251_22. PubMed 36578741 ↗

Individual participant data

Plan to share: Undecided

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06158061
Lead sponsor
Sohag University
Responsible party
Mariam Magdy Mounir (resident in dermatology department of Sohag Psychiatric hospital, Sohag University) — Principal investigator
First posted
Dec 6, 2023
Start date
Jan 24, 2024 (estimated)
Primary completion
Aug 15, 2024 (estimated)
Completion
Aug 15, 2024 (estimated)
Last update
Dec 6, 2023

Study contacts

Mariam M Monir, resident
Contact
mariem_magdy_post@med.sohag.edu.eg
01280924345
Mohammed A Ali, professor
Contact

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion